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ABSTRACT 
The prevalence of peripheral artery disease (PAD) is increasing worldwide and is 
estimated to affect about 360 million patients by 2030. Patients with PAD are at a higher risk 
of premature mortality and suffer from disability and functional impairment, both of which 
contribute to the direct and indirect socioeconomic burden of PAD. These trends are occurring 
despite emphasis towards control of traditional risk factors and interventions to decrease the 
impact of PAD on patient outcomes. Hence it is critical to identify and study novel risk factors 
that could impact outcomes in patients with PAD.  
Chronic mental stress could be one such factor. Mental stress is a potent 
cardiovascular risk factor and has been associated with development and progression of 
coronary disease and worse outcomes, including higher risk of mortality and poorer quality of 
life in patients after a myocardial infarction. However, there is paucity of evidence for the 
association of chronic mental stress with outcomes in PAD.  
To address this critical gap in understanding the link between mental stress and 
outcomes in PAD, we used data from the Patient-centered Outcomes Related to Treatment 
practices in peripheral Arterial disease: Investigating Trajectories (PORTRAIT), an 
international registry of patients presenting with symptoms of PAD. Mental stress was 
quantified at baseline, 3-, 6- and 12-month follow-up using the validated 4-item Perceived 
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Stress Scale (PSS-4). For each patient available PSS-4 scores from all time points were 
averaged to quantify a subject’s average exposure to mental stress over one year. To examine 
the association of chronic stress with longitudinal mortality and health status outcomes, we 
did two separate landmark analysis. First to examine the impact of chronic stress on mortality 
we did a landmark analysis starting at 12-month follow-up. For each patient we defined 
chronic stress to be average of PSS-4 score at baseline through 12-months. Cox regression 
models adjusting for patients’ demographics (age, sex, race), comorbid conditions (diabetes, 
hypertension, history of myocardial infarction, congestive heart failure, smoking status), 
baseline ankle-brachial index, invasive treatment for PAD, socioeconomic indicators (highest 
education level, avoidance of care due to cost and end of the month resources),  were used to 
assess an independent association of average stress (over first year of follow-up) with all-
cause mortality over the subsequent four years.  
Second, to examine the association of chronic stress with 12-month health status 
outcomes we defined chronic stress exposure to be average PSS-4 score across baseline, 3- 
and 6-month follow-up assessments. This quantified a patient’s exposure to chronic stress 
over first 6-months of follow-up. Health status was quantified at baseline and 12-months. 
PAD specific health status was assessed using the PAD Questionnaire (PAQ). Generic health 
status was assessed using the EuroQoL Visual Analog Scale (EQ5D VAS). Hierarchical 
multivariable regression models, with random effects for site and adjustment for country, 
patients’ demographics, comorbid conditions, baseline ABI, treatment strategy and 
socioeconomic status-were used to examine independent association of average stress 
(baseline to 6-months) on recovery in health status at 12-months. 
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In in patients in whom accurate assessment of chronic mental stress and mortality 
could be made (n=757, mean age 68.5 ± 9.7, 42% females, 28% non-Caucasians), higher 
average stress scores over 12-months were associated with greater hazards of mortality, in the 
adjusted model (hazard ratio per +1 unit increase in average PSS-4 1.08, 95% CI 1.01, 1.16 
p=0.03). Similarly, in patients who had complete assessment of chronic stress over 6-months 
and health status at baseline and 12-month follow-up (n=1060, mean age 67.7, 37% females, 
17.7% non-Caucasian) higher averaged stress scores over 6-months were associated with 
poorer PAQ summary score at 12-months in completely adjusted models (-1.4 points per +1-
point increase in average PSS-4 95% CI -2.1, -0.6 p <0.001).  
Chronic stress in patients with PAD, is independently associated with higher mortality 
risk and poorer health status outcomes. These results set the stage for exploring interventions 
to examine if strategies to reduce chronic stress in patients with PAD improves outcomes.  
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CHAPTER 1 
INTRODUCTION 
Global Burden of Peripheral Artery Disease 
Peripheral Artery Disease (PAD) is characterized by debilitating atherosclerotic occlusion of 
arteries in the lower extremities.1,2 The prevalence of PAD is increasing worldwide, and PAD is 
now recognized as a growing global health concern.3 It is estimated that by 2030, more than 300 
million people worldwide will be affected by PAD.4  The prevalence of PAD rises sharply with 
age and it affects a substantial proportion of the elderly population.5    
 PAD is a devastating disease and directly impacts a patient’s functioning, productivity 
and increases risk of premature mortality.1,6,7 These outcomes contribute to direct and indirect 
socioeconomic burden of PAD and represent a colossal public health issue. Over the past 20 
years there has been a global increase in death and disability from PAD.1,8 Average 5-year 
mortality for patients with PAD continue to be about 25%, comparable to mortality rates of 
patients after a myocardial infarction or heart failure.9 Most of the patients with PAD die of 
cardiovascular causes.10 This data underscores that patients with symptomatic PAD have a high 
cardiovascular risk and highlights the importance of interventions to attenuate the risk. 
Additionally in the US, average annual cost for a patient with PAD is estimated to be 
about $11,000.11 This direct cost of PAD compound lost wages, care by family members and lost 
opportunity costs, increasing the socioeconomic burden of PAD. It is important to realize that 
patients with PAD continue to suffer from these adverse outcomes despite significant advances 
in treatments including medications, supervised exercise and revascularization. Hence, it is 
critical to identify novel risk factors that put patients with PAD at higher risk so that 
interventions that seek to improve patients’ outcomes can be designed.  
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Mental Stress, a Potent Cardiovascular Risk Factor 
To understand the impact of stress on an individual’s life it is important to conceptualize stress in 
terms of a relative imbalance between coping skills and external stimuli. Three different models 
of understanding the stress construct have been described. Stress has been viewed as a response, a 
stimulus and a transaction.12,13  
 Stress, in a response model is considered dependent to a stimulus. It ranges across a 
spectrum of response pattern and follows three stages; alarm, resistance and exhaustion. When 
confronted with a negative stimulus the alarm response initiates the sympathetic system to combat 
or avoid the stressor. The resistance response then activates the fight or flight reaction to the 
stressor, returning the system to homeostasis, reducing harm, or more generally, accommodating 
the stressor which can lead maladaptive responses such as sleep deprivation, hypertension, 
hyperglycemia etc., until the body’s reserves are exhausted.12  
 The stimulus model of stress views stress as a significant life event or change that demands 
response, adjustment or adaption.12 Holmes and Rahe created the Social Readjustment Rating 
Scale consisting of 42 life events scored according to the estimated degree of adjustment they 
would demand.14 They theorized that stress was the independent variable in stress-coping equation, 
the cause of an experience, rather than the experience itself. 
 In order to explain stress as a dynamic process, Lazarus and Folkman introduced the 
transactional model of stress.15 This model presents stress as a transaction between a person and 
his/her environment. Depending on the amount of demands that a person is confronted with and 
the amount of resources that they have to deal with the demands, stress may either be in abundance 
or avoided completely. Whenever confronted with a new situation, an individual analyzes if a 
situation is a threat or not. This is the primary appraisal. If the situation is perceived to be a threat, 
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a secondary appraisal occurs, where an individual decides if he/she can deal with the stressor. If 
the perceived demands outweigh the mental resources required to deal with them, stress occurs. 
Figure A2 describes the transactional model of stress.  
 Regardless of the construct used to define it, stress is a potent cardiovascular risk factor.16 
It occurs when external and internal stressors overcome an individual’s mental reserves.17 
Exposure to chronic mental stress is associated with adverse health behaviors such as obesity18, 
smoking19 , lack of exercise20 and use of illicit drugs.21 Additionally, various pathophysiological 
processes that enhance atherosclerosis and development of cardiovascular disease are triggered by 
exposure to mental stress. These include, increase in blood pressure22, platelet reactivity23, 
endothelial dysfunction24, hyperglycemia25 and inflammation.26 Additionally, in patients with a 
devastating disease such as PAD chronic stress further complicates management as stress is 
associated with decreased compliance and delays in seeking care. Through interplay of these 
mechanisms chronic stress is thought to increase overall cardiovascular risk and progression of 
atherosclerotic disease.  
Higher exposure to mental stress at the time of myocardial infarction is independently 
associated with higher risk of mortality and poorer quality of life of patients.27 In asymptomatic 
women, chronic stress due to marital issues was associated with about three times higher risk of 
development of cardiovascular disease.28 Furthermore, mental stress at workplace was associated 
with higher risk of future events in patients with coronary artery disease.29  
However, it is important to realize that mental stress is a modifiable risk factor for which 
evidence-based treatments exist.30 Equipping patients with coping skills to reduce stress in their 
lives has been shown to be effective in improving quality of life in patients with coronary artery 
disease. Additionally, chronic stress management through cognitive behavioral therapy programs 
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as well through transcendental meditation in addition to standard care has been shown to reduce 
the risk of recurrent cardiovascular events and increased life expectancy after a myocardial 
infection.31,32  
The Case for Studying Mental Stress as a Risk Factor in Peripheral Artery Disease 
Patients with PAD suffer from adverse outcomes, including higher risk of mortality and 
disability. It is also known that about a third of the patients with PAD report high levels of self-
perceived stress at initial presentation.33 As stress has a strong relationship with development and 
progression of coronary artery disease and given similar mechanisms underlie the 
pathophysiological pathway to PAD, it is important to examine if there is an association of 
exposure to stress with outcomes in patients with PAD. Additionally, patients with PAD are at a 
high risk for adverse cardiovascular events. There is a paucity of data on impact of exposure to 
mental stress with outcomes in PAD. Some studies have examined the association of stress and 
anxious personality traits with health status of patients with PAD.34,35 However, these studies 
either looked at cross-sectional associations and did not account for changes in stress levels over 
time. Additionally, no prior study has examined the association of chronic exposure to stress 
with mortality risk in patients with PAD.  
To address these gaps in knowledge we sought to 1) examine the association of chronic 
exposure to stress with mortality in patients with PAD; 2) Examine the association of chronic 
exposure to stress with generic and disease specific health status of patients with PAD. We 
hypothesized that patients who had greater exposure to chronic stress would have higher risk of 
mortality and poorer generic and disease specific health status.  
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CHAPTER 2 
METHODOLOGY 
Study Design and Participants 
The Patient Centered Outcomes Related to Treatment Practices in Peripheral Arterial 
Disease: Investigating Trajectories (PORTRAIT; NCT01419080) study is a prospective 
observational registry that enrolled patients with a new diagnosis or worsening of symptoms of 
PAD, that presented to subspecialty clinics in the US, Netherlands and Australia (Figure 1). 
Details of study design and methodology has been described extensively.36 Figure 2 illustrates 
the study design. For this analysis we used data from baseline, and all follow-up time points. 
Additionally, data on mortality (for US patients only) up to 5-year after enrollment was used. 
Patients were enrolled at the PAD specialty clinics that included general cardiology, 
interventional cardiology, interventional radiology, or vascular surgery offices. Baseline 
interview was conducted by trained study personnel to obtain information about patients’ quality 
of life, symptoms and functioning. Standardized case report forms were used to abstract clinical 
information (medical history, PAD history, weight, height, and medications) from patients’ 
medical records. Serial information about patients’ health status and lifestyle factors was 
collected at 3, 6, and 12 months of follow-up through telephone interviews. Patients presenting 
to specialty clinic with symptoms of PAD and an ankle brachial index (ABI) ≤ 0.90 or a 
significant drop in post-exercise ankle pressure (≥20mm of Hg) were enrolled. Patients with non-
compressible ABI ≥ 1.30, critical limb ischemia, lower-limb revascularization in the 12 months 
prior to the PAD visit and those who were incarcerated, hard of hearing or unable to provide 
informed consent were excluded. Table 1 describes the inclusion and exclusion criteria in detail. 
All participating centers obtained IRB approval and all patients provided informed consent at 
enrollment.  
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Figure 1: PORTRAIT enrolling sites.  
(a) United States 
 
 
 
(b) Netherlands 
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(c) Australia 
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Figure 2. Study Design 
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Table 1. Inclusion and Exclusion Criteria for PORTRAIT study.  
Inclusion Criteria Exclusion Criteria 
▪  Age ≥ 18 years 
▪ New-onset or recent exacerbation of 
exertional leg symptoms, regardless of 
whether symptoms are typical or atypical 
(buttock, thigh, hip or calf pain, numbness 
or discomfort inhibiting the patient’s 
ability to walk distances)  
▪ Ankle-brachial index = resting ankle-
brachial index assessment ≤0.90 or drop in 
post-exercise ankle pressure ≥20mmHg 
▪ Non-compressible ankle-brachial index  ≥1.30 
▪ Patient had a lower-limb revascularization 
procedure in the ipsilateral leg (=same leg) where 
the patient is currently having symptoms in the 
past year (atherectomy, endarterectomy, bypass 
surgery, angioplasty) 
▪ A current episode of critical limb ischemia 
(ischemic rest pain, ulceration or gangrene) 
(Fontaine III, IV, or Rutherford grade IV-VI) 
▪ Non-English speaking or non-Spanish speaking 
for US sites; Non-Dutch speaking for Dutch sites; 
Non-English speaking for Australian sites 
▪ Hearing impairment 
▪ Currently a prisoner 
▪ Patient previously enrolled in PORTRAIT 
▪ Unable to provide written informed consent 
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Assessment of Chronic Mental Stress 
Each patient’s perception of their ability to deal with the stress in their lives was 
quantified at baseline, 3-, 6- and 12-month follow-up using the 4-point Perceived Stress Scale 
(PSS-4). The PSS-4 is a reliable (Cronbach’s alpha 0.67-0.79) and valid measure of a subject’s 
self-evaluation of control and confidence in handling the stressful situations over the past 
month.17  PSS-4 consists of four questions comprised of rating scale responses. Figure 2 lists the 
questions in the PSS-4. Scores range from 0-16, with higher scores indicating stress exceeding a 
subject’s ability to cope. As the PSS-4 is a non-diagnostic instrument, there are no established 
thresholds, and scores are compared to a normative value in the general population.17,37 In the 
English population a score ≥ 6 was found to depict patients with high levels of stress.37 A score ≥ 
6 was also found to be associated with adverse outcomes in patients after a myocardial 
infarction. Hence, in keeping with prior research we used a score of ≥ 6 to describe patients with 
high levels of self-perceived stress.27  
 Stress is an everyday phenomenon, and exposure to stress over time could incrementally 
increase a patient’s cardiovascular risk. We wanted to examine the association of chronic stress 
with outcomes in PAD.  Hence to depict each patient’s chronic exposure to stress, we averaged 
the PSS-4 assessments. To examine the association with 12-month health status outcomes, we 
averaged the PSS-4 across first 6-month follow-up and for mortality assessment over 5-years we 
averaged PSS-4 scores over the first 12-month follow-up (figure 3) 
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Figure 3. Exposure to chronic stress for examining association with mortality and health 
status.   
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Figure 4. 4-Point Perceived Stress Scale 
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Assessment of Health Status 
Disease specific health status was assessed using the PAD Questionnaire (PAQ) (Figure A-1). 
PAQ is a 20-item multidimensional instrument that is a valid, reliable and responsive disease 
specific measure of patients with PAD.38,39 A single item identifies the more symptomatic limb 
and remaining 19 are answered according to variable rating response scales to assess 6 domains, 
physical limitation, symptoms, symptom stability, social limitation, treatment satisfaction and 
QoL. The PAQ summary score (PAQ SS) integrates all domains except symptom stability and 
treatment satisfaction. Scores range from 0-100 with higher scores indicating less functional 
limitation, fewer symptoms, better treatment satisfaction, higher social functioning and better 
QoL. A change ≥ 8-points on the PAQ SS was found to be a clinically meaningful difference. 
The PAQ has been translated and validated in the Dutch population.40  
 Generic health status was assessed using the EuroQoL Visual Analog Scale (EQ5D 
VAS).41 The VAS is a measure of perceived general health that consists of a single item “feeling 
thermometer”, on which the patients rate their general health state from 0 (worst imaginable) to 
100 (best imaginable).41 Health status assessments from baseline and 12-months were used to 
examine impact of chronic stress on a patient’s functionality, symptoms and quality of life.  
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Assessment of Mortality  
Data on mortality was only available for patients from the US. Hence analysis to examine the 
association of chronic stress with mortality was only done in the US cohort of the PORTRAIT 
study. For the US patients vital status information over follow-up (median 49-months) was 
obtained for those who were alive 12 months following their enrollment through querying the 
National Death Index (NDI).42 The NDI provides reliable and accurate data regarding vital status 
of patients from the US. All-cause mortality was the primary outcome for this analysis.43  
 To understand the common causes of death, international classification of disease (ICD) 
codes for the cause of death as listed in the NDI dataset were examined. After 1999, causes of 
death have been reclassified by ICD 10 codes in the NDI database.43 We categorized causes of 
death as cardiovascular cause, presumed cardiovascular cause and non-cardiovascular death, as 
used in previous work.44 Cardiovascular cause of death was considered if the ICD-10 code 
indicated myocardial infarction, ischemic heart disease, heart failure or cardiac arrest as the 
cause of death. Presumed cardiovascular cause of death was implied if the ICD-10 code 
indicated pulmonary embolism, cerebrovascular accident or PAD as cause of death. The 
remainder of causes of death were categorized as “other”. 
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Covariates 
Socioeconomic status was assessed using patient responses to questions regarding their highest 
level of education (high school/college/post graduate), prior avoidance of care due to costs 
(yes/no) and typical financial resources left at the end of the month (some/just enough/not 
enough). Treatment strategy at 3 months following patients’ PAD work-up was categorized as 
either invasive (including percutaneous or surgical interventions) or non-invasive (medical 
therapy only). Depressive symptoms at baseline were assessed using the 8-item Patient Health 
Questionnaire depression scale (PHQ-8), a screening instrument for major depression.45 Scores 
range from 0-24 with higher score indicating greater depressive symptoms.45 Score ≥ 10 are 
considered to imply clinically relevant symptoms that warrant further assessment.45 
Statistical Analysis 
For descriptive analyses the analytical cohort was dichotomized based on patients 
averaged stress scores over 6-months as high (average PSS-4 ≥ 6) vs. low (average PSS-4 <6). 
Patient demographics, PAD severity, treatment strategy and comorbidities at baseline were 
compared in patients with high and low chronic stress. Continuous variables were presented as 
means ± standard deviations and were compared across groups using independent t-tests for 
independent samples or Mann-Whitney U tests for non-normally distributed variables.  
Categorical variables were presented as frequencies with percentages and were compared using 
Chi-square tests.  
 To examine the association of chronic stress with patient’s health status trajectories, 
mean PAQ and VAS scores at each assessment in patients with high and low levels of chronic 
stress were plotted. To examine the association of averaged stress scores with recovery in 
generic and disease specific health status at 12-months we did a land mark analysis starting at 6-
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month follow up. We fit hierarchical multivariable regression models, with fixed effect for 
country and random effect for site to account for clustering at the site level, with exposure being 
average PSS-4 scores over 6-months and outcome being health status scores at 12-months. 
Several models were defined a priori, and a step-wise modelling approach was used. In model 1 
the unadjusted association of average PSS-4 score with change in health status at 12-months, 
(except for adjusting for baseline health status) was assessed. In model 2 additional adjustment 
for patient demographics (age, sex and race) was done. As stress has been associated 
development of diabetes22, hypertension46, myocardial infarction47, heart failure48 and uptake of 
smoking22, in model 3, additional adjustment for these covariates as well as PAD severity 
(assessed with baseline ABI) and treatment type (invasive/medical) was done. This was to assess 
if there remained an independent association after accounting for these factors; which could 
potentially have either a confounding or mediating effect, or both.  Additionally, socioeconomic 
status has been associated with outcomes in patients with PAD.49 Hence we constructed Model 4 
with additional adjustment for socioeconomic status.   
 Accurate assessment of mortality was not available for patients from the 
Netherlands and Australia. Hence mortality analysis was limited to patients form the US.  For the 
US-patients the association between average PSS-4 scores over 12 months with 4-year all-cause 
mortality after the initial 12-month follow up period was assessed, using a landmark analysis 
with time zero defined at 12-months. Patients who had died by 12-months (n=31) were excluded 
from this analysis. Kaplan-Meier curves to compare the age-adjusted risk of all-cause mortality 
over the following 4-years, in patients with high and low levels of stress were constructed, and 
statistical significance was tested using the log-rank test.   
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To examine the independent association of averaged PSS-4 score (as a continuous 
variable) with all-cause mortality over 4 years after the 12-month follow-up, hierarchical Cox 
regression models with a random effect for enrollment site were constructed. As with the health 
status linear regression models. four models were defined a priori. Model 1 unadjusted 
association (except for site and age) was examined. Model 2 was additionally adjusted for patient 
demographics (sex and race). Model 3 consisted of model 2 and further adjusted for 
comorbidities (diabetes, hypertension, history of myocardial infarction, congestive heart failure, 
current smoking status), baseline ABI and treatment type. Model 4 consisted of model 3 and 
further adjustment for socio-economic status variables (education, avoiding care due to costs, 
and end-of-the-month financial resources). 
 As chronic stress may overlap with depressive symptoms, we assessed the 
correlation of baseline PHQ-8 and PSS-4 scores using Pearson’s correlation coefficient. Finally, 
in our completely adjusted models for examine health status and mortality we added baseline 
PHQ-8 score to assess whether chronic stress outside of the context of possible depression was 
associated with patient’s health status and mortality risk.   
All models included restricted cubic splines for estimating effects of continuous variables 
to accommodate non-linear relationships. In cases where no significant evidence of non-linearity 
was found, associations were re-estimated using linear effects to simplify interpretation. All 
statistical analyses were performed using SAS 9.4 (SAS Institute Inc, Cary, NC). All statistical 
tests were 2-tailed and significance was determined using α = 0.05.  
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CHAPTER 3 
RESULTS 
Derivation of Study Cohort and Baseline Characteristics 
After excluding patients who had missing baseline PSS-4 assessment (n=21), missing and 
patients who had missing health status assessment at 12-months (n=194), our final study cohort 
included 1060 patients. For examining the impact of stress on mortality, only data form patients 
from US was used, as accurate assessment of mortality was not available for non-US patients 
(n=303). Figure 5 shows the derivation of the analytical cohorts. Table A-1 compares the 
differences in the patients who were excluded and those who were not. Patients who were 
excluded had a higher mean PHQ-8 score and were less likely to have at least high school level 
of education and have hypertension. There were no significant differences in demographics or 
prevalence of other comorbidities. In our study cohort 198 patients had averaged PSS-4 score ≥ 
6, and 862 patients had averaged PSS-4 scores <6. Mean age was 67.7 ± 9.3 years, 37.1% 
(n=393) of the patients were females and 82.3% (n=872) were white. Comorbidities were highly 
prevalent with 80.9% (n=858) patients having hypertension, 19.6% (n=208)  having history of 
myocardial infarction, 32.5% (n=345)  having diabetes,  9.7% (n=103)  having congestive heart 
failure, 36.4% (n=386)  being active smokers and 14.1% (n=149) having clinically relevant 
depressive symptoms (PHQ-8 ≥10). 9.7% (n=103) reported not having enough finances left at 
the end of the month to make ends meet, and 70.1% (n=743) reported having at least high school 
education.  
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Figure 5: Derivation of analytical cohorts. 
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Table 3 describes the baseline demographic and clinical characteristics of patients 
stratified by high (≥6) and low (<6) average PSS-4 score. Patients with high average stress 
(n=198) were younger, more likely to be females and less likely to be white. Additionally, 
patients with high average stress had greater prevalence of diabetes, hypertension, congestive 
heart failure and were less likely to get invasive treatment. There were no significant differences 
in baseline ABI, and prevalence of cancer and history of myocardial infarction or stroke. More 
patients with high chronic stress reported not having enough finances left at the end of the month 
and avoiding care due to costs. Moreover, depressive symptoms were significantly more 
common in patients with higher stress.      
 
Table 2. Baseline characteristics of patients with high vs low chronic stress level. 
 PSS-4 Score ≥ 6 
n=198 
PSS-4 Score <6 
n=862 
P value 
Demographics 
Age (Mean ± SD) 65.2 ± 9.5 68.2 ± 9.2 < 0.001 
Female Sex (%) 44.9 35.3 0.01 
White (%) 70.7 84.9 < 0.001 
Comorbidities and treatment (%) 
Current smoker 40.9 35.4 0.32 
Diabetes 41.9 30.4 0.001 
Hypertension 85.4 79.1 0.02 
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Congestive Heart Failure 14.6 8.6 0.009 
Chronic Kidney Disease 11.6 10.6 0.67 
Cancer 11.6 9.6 0.40 
Osteoarthritis 8.6 9.2 0.78 
Sleep Apnea 11.6 7.8 0.08 
Chronic Back Pain 13.6 14.0 0.88 
Coronary Artery Disease 51.0 42.7 0.03 
History of MI 23.7 18.7 0.11 
History of stroke 11.6 11.6 0.81 
Invasive Treatment Strategy 18.3 28.2 0.004 
ABI (Mean ± SD) 0.65 ± 0.20 0.67 ± 0.18 0.20 
Rutherford Classification of Symptoms (%) 
Mild Claudication 16.8 23.9  
<0.001 Moderate Claudication 45.7 50.0 
Severe Claudication 37.6 26.1 
Socioeconomic Status (%) 
High school education 73.1 69.9 0.37 
Not enough money left at 
month end 
24.4 6.7 <0.001 
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Avoiding care due to cost 25.0 11.4 <0.001 
Work for pay 46.2 36.4 0.25 
Depressive Symptoms at Baseline 
PHQ-8 ≥ 10 (%) 41.0 8.2 < 0.001 
PHQ-8 (Mean ± SD) 8.5 ± 6.4 3.6± 3.8 < 0.001 
Ankle Brachial Index (ABI), Myocardial Infarction (MI), 8-point patient health 
questionnaire (PHQ-8),  
 
 
 
 
Association of Chronic Stress with Health Status Outcomes 
Overall in the study cohort the mean PAQ Summary Score at baseline and 12-month 
follow-up was 49.6 ± 21.6 and 70.1 ± 25.5 respectively. Mean VAS was 66.6 ± 19.0 at baseline 
and 70.2 ± 17.8 at 12-month follow-up. Figure 4 describes the trajectories of disease-specific and 
generic health status in patients with high and low levels of chronic stress. Patients who 
perceived high levels of chronic stress had poorer disease-specific health status (across all PAQ 
domains) as well as generic health status (VAS) at baseline and all follow-up assessments.   
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Figure 6. Trajectory of generic and disease-specific health status in patients with high and 
low chronic stress. [PAQ= Peripheral Artery Disease Questionnaire] 
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Figure 5 and 6 show the association of average PSS-4 scores with recovery in PAQ summary 
score and VAS at 12-months. In completely adjusted models accounting for potential 
confounding factors including patient demographics, comorbidities, disease severity, treatment 
type and socioeconomic status, higher stress scores were associated with lower PAQ SS (-1.4  
points per +1-point increase in average PSS-4 95% CI -2.1, -0.6 p <0.001) and VAS (-1.2 points 
per +1-point increase in average PSS-4 95% CI -1.6, -0.8 p <0.001) at 12-months. After 
accounting for depressive symptoms (by adjusting for averaged PHQ-8 score), the association 
between chronic stress and 12-month change in PAQ summary score attenuated (-0.10 points per 
+1-point increase in PSS-4 95% CI -0.7, 0.5 p=0.75). However there remained a significant 
association of chronic stress with 12-month change in VAS (-0.5 points per +1-point increase in 
PSS-4 95% CI -0.9, 0.00 p=0.05). 
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Figure 7. Association of a single point increase in averaged PSS-4 with disease specific 
health status in patients with peripheral artery disease. [PAQ= Peripheral Artery Disease 
Questionnaire] 
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Figure 8. Association of a single point increase in averaged PSS-4 with generic health status 
in patients with peripheral artery disease.  
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Association of Chronic Stress with Mortality 
In patients who were alive at 12-month follow up the crude (unadjusted) mortality rate 
over follow-up was was 20.50%. In Figure 7, age-adjusted Kaplan-Meir curves are presented by 
high vs. low stress level groups. The log-rank test for this comparison was p=0.01.  
 
 
 
 
Figure 9. Kaplan Meier survival curve (landmarked at 1-year) in patients with high vs. low 
averaged stress scores over 1-year follow-up. (4-item Perceived Stress Scale [PSS-4]) 
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Table 5 describes the association of higher average PSS-4 score (per +1-unit increase) 
with mortality. Higher average stress scores over 12-months were associated with greater 
hazards of mortality, in both only age adjusted model (hazard ratio per +1 unit increase in 
average PSS-4 1.09, 95% CI 1.03, 1.17 p=0.006) and completely adjusted model (hazard ratio 
per +1 unit increase in average PSS-4 1.08, 95% CI 1.01, 1.16 p=0.03).  
Table 3. Association of + 1 unit increase in averaged PSS-4 score with all-cause mortality in 
patients with PAD.  
Model Hazard Ratio (95% CI) p value 
Model 1 1.09 (1.03, 1.17) 0.006 
Model 2 1.10 (1.03, 1.18) 0.004 
Model 3 1.08 (1.01, 1.158) 0.03 
Model 4 1.08 (1.01, 1.16) 0.03 
Model 1: unadjusted (except for age and enrollment site), Model 2: additionally, adjusted for 
sex and race, Model 3: additionally, adjusted for history of diabetes, hypertension, myocardial 
infarction, congestive heart failure, smoking status, baseline ABI and treatment type. Model 4: 
additionally, adjusted for SES (highest level of education, avoidance of care due to costs, end 
of the month financial distress).  
 
To understand if chronic stress had a differential impact on mortality in patients across 
different age-groups, we did a post-hoc analysis to test the interaction of age with mortality. 
There was no interaction (p>0.1). However, patients with high chronic levels of stress in the age 
bracket 61-75 had higher event rates compared with patients having low chronic stress in the 
same age bracket (18.30-56.80% in high stress vs 8.50-25.50% in low stress groups). Table 4 
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describes the unadjusted event rates in patients with high and low chronic stress stratified by age 
groups.   
Table 4. Unadjusted Kaplan Meier estimates of event rates in patients with high and low 
averaged stress score over 1-year follow-up, stress stratified by age quartiles.   
 Age 42-60 Age 61-69 Age 70-75 Age 76-95 
PSS-4 Score ≥ 6 9.3% 
(n=71) 
18.3% 
(n=32) 
56.8% 
(n=19) 
34.2% 
(n=25) 
PSS-4 Score < 6 8.5% 
(n=98) 
8.5%  
(n=174) 
25.5% 
(n=155) 
34.3% 
(n=183) 
4-item Perceived Stress Scale (PSS-4) 
 
Table A-2 lists all the ICD-10 codes used for cause of death adjudication, stratified by 
cardiovascular causes, presumed cardiovascular causes and other causes. Cardiovascular causes 
accounted for 30% (n=46), presumed cardiovascular causes for 4.6% (n=7) and other causes 
accounted for 65% (n=100) of the deaths respectively.  
PHQ-8 and PSS-4 scores were significantly correlated with a shared variance of 29% 
(Pearson’s correlation coefficient 0.54 p<0.001). After accounting for depressive symptoms (by 
adjusting for averaged PHQ-8 score), the association between chronic stress and 12-month 
change in PAQ summary score attenuated (-0.10 points per +1-point increase in PSS-4 95% CI -
0.7, 0.5 p=0.75). However there remained a significant association of chronic stress with 12-
month change in VAS (-0.5 points per +1-point increase in PSS-4 95% CI -0.9, 0.00 p=0.05). 
For mortality assessment after adjusting for baseline PHQ-8 score the association of chronic 
stress with mortality, did not meaningfully change (hazard ratio per +1 unit increase in average 
PSS-4 1.09 95% CI 1.00, 1.18 p=0.06).  
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CHAPTER 4 
 
DISCUSSION 
With a growing population of patients presenting with PAD, it is critical to examine 
factors associated with worse outcomes as a strategy for identifying potential novel therapeutic 
strategies to further improve care. In high risk population, such as patients with PAD, decreasing 
risk of premature mortality is an important focus. Additionally, health status outcomes directly 
assess the impact of disease’s symptoms, function and quality of life, and optimizing health 
status is an important goal of treatment.50  In this real-world contemporary registry of patients 
with new or worsening PAD symptoms, we found that 19% of the patients had high chronic 
stress levels in the year following their PAD work-up. Higher exposure to chronic perceived 
stress was significantly associated with both an increased risk of mortality and poorer health 
status. This relationship was independent of patients’ baseline ABI, major comorbidities, 
treatment type and socio-economic status. Our study demonstrates the prognostic importance of 
chronic stress in PAD and sets the stage for further exploration into stress reduction programs for 
PAD populations as a strategy to improve outcomes. 
 Previous studies have shown that perceived stress and a distressed personality are 
commonly present in patients with PAD and linked with worse health status and quality of life 
However these studies have only assessed generic measures of health status and only examined 
select populations without specifically quantifying patients’ chronic mental stress. Our findings 
substantially extend these insights by using data for patients enrolled at similar time point for 
progression of PAD (development of new symptoms), use of validated instrument (PSS-4) to 
assess patients chronic self-perceived stress at multiple assessments over a 12-month follow-up 
period and looking at longitudinal association with health status and mortality. 
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 Chronic mental stress is associated with development and progression of cardiovascular 
disease 51. The mechanisms underlying this association are complex and multi-faceted (Figure 
A-3). These include development of adverse health behaviors such as physical inactivity20, 
obesity22 and smoking.19 Stress is also associated with pathophysiological pathways leading to 
development of higher blood pressure46, insulin resistance22, enhanced activity of hypothalamic 
pituitary axis25, platelet reactivity23 and inflammation.26 Moreover, patients with higher stress are 
less likely to be compliant with treatment and may present with vague symptoms causing 
treatment delays.51 Through interplay of these complex processes, stress has been recognized as 
a strong independent determinant of outcomes in patients with atherosclerotic vascular disease.  
 Chronic stress can manifest itself in the context of other psychiatric conditions 
such as depression, or can present itself without having a clinical diagnosis for a mental 
condition and various idiosyncratic triggers can cause individuals to feel overwhelmed by stress 
such as marital28 and financial strain52, job insecurity29, etc. It has been shown that high 
perceived stress is a potent risk factor for the development and progression of coronary artery 
disease and cardiovascular death.47,53 Moderate to high mental stress levels at the time of 
myocardial infarction has been associated with a 40% higher risk of dying in the 2 years 
following the event.27 However, interventions to mitigate the impact of stress have shown to 
improve outcomes. In patients discharged after a myocardial infarction, percutaneous coronary 
interventions or coronary artery bypass graft surgery, cognitive behavior therapy to equip 
patients to deal with stress in addition to standard care decreased the risk of mortality and 
recurrent events.31 Similarly in patients with stable coronary artery disease transcendental 
meditation in addition to standard therapy reduced the risk of mortality.32 Given the strength of 
the association found in our study and the fact that this risk factor has been largely ignored in the 
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PAD population, there appears to be an important need for studies to test the efficacy of stress 
management strategies on cardiovascular outcomes in patients with PAD. Patients with PAD are 
at high risk of adverse events. Control of traditional risk factors along with strategies to mitigate 
the impact of non-traditional risk factors such as stress could improve outcomes in this 
vulnerable population (Figure A-4).   
This study should be interpreted within the context of the following limitations. First, the 
observational design of this study precludes any inferences about causation. In an absence of a 
randomized clinical trial, it cannot be determined if evidence-based strategies to manage chronic 
stress will result in improved health status and decrease mortality risk in patients with PAD. 
However, even after extensively adjusting for factors that could be along the causal pathway 
between exposure to stress and patient’s health status, a significant and strong association with 
poorer health status and higher mortality risk with higher exposure to stress remained. This sets 
the stage for future efforts to explore if reduction in patient’s chronic stress level can improve 
outcomes in PAD. Secondly, the sites that recruited patients for the PORTRAIT study may not 
be representative of other vascular clinics that were not represented in this study.  
 
Conclusion 
In a large multi-center contemporary registry of patients presenting with new or 
worsening symptoms of PAD, we found that high self-perceived stress levels are common in 
patients with PAD. There is a strong and independent association between higher chronic 
perceived stress levels in the year following a PAD diagnosis and a higher 4-year mortality risk. 
Additionally, across a broad spectrum of PAD-specific health status assessments quantifying the 
impact on patient’s symptoms, functioning and quality of life as well as measures of generic 
health status, recovery in health status in patients with PAD was adversely impacted by higher 
 33 
 
 
chronic self-perceived stress. These findings highlight the potential advantage of employing a 
more holistic treatment approach that includes assessment and management of patients’ mental 
health, including the experience of chronic stress and such a strategy should be tested to improve 
the outcomes of patients with PAD. 
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APPENDIX 
Table A-1. Baseline characteristics of patients who were included vs. those who were excluded 
from the study cohort.  
 Included 
n=1060 
Excluded 
n=215 
P value 
Demographics 
Age (Mean ± SD) 67.7 ± 9.3  67.3 ± 10.2 0.63 
Female Sex (%) 37.1 41.4 0.23 
White (%) 82.2 81.4 0.76 
Comorbidities and treatment (%) 
Current smoker 36.4 40.9 0.22 
Diabetes 32.6 36.3 0.29 
Hypertension 80.9 74.4 0.03 
Congestive Heart Failure 9.7 11.2 0.52 
Chronic Kidney Disease 11.0 10.6 0.25 
Cancer 10.0 10.7 0.76 
Osteoarthritis 9.0 10.2 0.59 
Sleep Apnea 8.5 6.0 0.23 
Chronic Back Pain 14.0 12.1 0.47 
History of MI 19.6 15.8 0.19 
History of stroke 11.1 13.5 0.32 
Invasive Treatment Strategy 24.4 26.6 0.42 
ABI (Mean ± SD) 0.67 ± 0.19 0.66 ± 0.19 0.91 
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Socioeconomic Status (%) 
High school education 70.1 60.5 0.02 
Not enough money left at 
month end 
9.7 14.4 0.12 
Avoiding care due to cost 13.9 14.4 0.80 
Depressive Symptoms at Baseline 
PHQ-8 (Mean ± SD) 4.5 ± 4.8 5.9± 5.9 <0.001 
    
Ankle Brachial Index (ABI), Myocardial Infarction (MI), 8-point patient health 
questionnaire (PHQ-8),  
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Table A-2. All ICD-10 codes for cardiovascular cause, probable cardiovascular cause and 
non-cardiovascular cause of death.   
Cause of Death Categorization ICD-10 codes 
Cardiovascular I251, I250, I219, I500, I255, I259, I119, I214, 
I248, I469, I509, I519,  
Presumed Cardiovascular I615, I739, I269, I64, I672 
Non-Cardiovascular I729, J151, J690, J841, K529, K566, K819, 
L039, M628, M869, N19, N288, N482, R092, 
R99, V092, X00, I272, I38, I210. G939, 
G062, J440, J961, J969, K559, N179, N185, 
N189, A047, B182, C169, C181, C189, C229, 
C23, C56, C80, C845, C911, C920, D381, 
D469, D649, D869, E117, A419, C259, 
C900, E149, G20, I48, C61, E119, E142, 
E785, G931, J449, C349 
International Classification of Disease (ICD) 
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Figure A-1. Peripheral Artery Disease Questionnaire.  
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Figure A-2. Transactional Model of Stress 
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Figure A-3. Mechanisms by which chronic stress impacts risk of adverse outcomes in 
patients with peripheral artery disease.  
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Figure A-4 Control of risk factors over time to improve outcomes in patients with 
peripheral artery disease.  
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Figure A-5 SAS code 
EXCLUSIONS 
AverageStressScore = mean(pssscore_b, pssscore_3, pssscore_6, pssscore_12); 
label averagestressscore = 'Average PSS Score over 12 months'; 
 
if not missing(Averagestressscore) then do; 
if averagesgressscore>=6 then avgpsspos = 1; 
else avgpsspos = 0; 
label avgpsspos = 'Average PSS Score >= 6'; 
format avgpsspos yesno.; 
end; 
 
if country = 1 then do; 
 if trttype = 1 then invtrt_3 = 0; 
 if trttype in (2,3) then invtrt_3 = 1; 
end; 
if country in (2,3) then invtrt_3 = invasivetrt_3; 
run; 
ods rtf file = "Exclusions &bettersysdate..rtf"; 
title 'Overall PORTRAIT Cohort'; 
proc sql; 
select count (distinct ptid) 
from portrait.patients; 
quit; 
 
title 'Have PSS Score at baseline'; 
proc sql; 
select count (distinct ptid) 
from portrait.patients 
where not missing(pssscore_b); 
quit; 
 
title 'Have Baseline PAQ Summary Scores'; 
proc sql; 
select count (distinct ptid) 
from portrait.patients 
where not missing(pssscore_b) and not missing(paqsumm_b); 
quit; 
 
title 'Have 12 month score'; 
proc sql; 
select count (distinct ptid) 
from portrait.patients 
where  not missing(pssscore_b) and not missing(paqsumm_b) and not missing(paqsumm_12); 
quit; 
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title; 
ods rtf close; 
 
BASELINE CHARACTERISTICS BY AVERAGE STRESS GROUPS 
*Categorical variable - chi square test; 
proc freq data=portrait.thesis; 
tables sex*psspos_b/chisq; 
run; 
 
*Continuous variable - t test; 
proc ttest data=portrait.thesis; 
class psspos_b; 
var age; 
run; 
 
%report; 
%set(data=portrait.thesis, columns=psspos_b\_total_, statndec=2, stat=meanpmsd mediqr, stddiff 
= t); 
%table; 
%section('Demographics'); 
%stat(age); 
%freq(sex); 
%freq(racewhite); 
%freq(currentsmoker); 
%freq(hxdm); 
%freq(hxhtn); 
%freq(hxchf); 
%freq(hxckd); 
%freq(hxcancer); 
%freq(hxosteoarth); 
%freq(hxsleepap); 
%freq(hxbackpain); 
%freq(hxcad); 
%freq(hxmi); 
%freq(hxcvatia); 
%freq(invtrt_3); 
%stat(abivalue); 
%freq(educhs_b); 
%freq(notenoughfinance); 
%freq(Avoidcarecost_b); 
%freq(workforpay); 
%freq(phq8depr_b); 
%stat(phq8score_b); 
%endtable; 
%endreport; 
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LINEAR REGRESSION MODELS FOR HEALTH STATUS 
 
MODEL 1 UNADJUSTED 
PAQ 
title1 'PAQ Summary'; 
title2 'Unadjusted - no spline'; 
proc glimmix data=portrait.thesis; 
class siteid; 
model paqsumm_12  = averagestressscore_w paqsumm_b; 
random intercept/subject=siteid; 
estimate 'Average Stress Score per 1 pt increase' AverageStressScore_w 1/cl; 
ods select modelinfo tests3 estimates; 
run; 
EQ5D VAS 
proc glimmix data=portrait.thesis; 
class siteid; 
model eq5d_12  = averagestressscore_w eq5d_b; 
random intercept/subject=siteid; 
estimate 'Average Stress Score per 1 pt increase' AverageStressScore_w 1/cl; 
ods select modelinfo tests3 estimates; 
run; 
MODEL 2 ADJUSTED FOR DEMOGRAPHICS 
PAQ 
proc glimmix data=portrait.thesis; 
class siteid sex racewhite country; 
model paqsumm_12  = AverageStressScore_w paqsumm_b age sex racewhite country; 
random intercept/subject=siteid; 
estimate 'Average Stress Score per 1 pt increase' AverageStressScore_w 1/cl; 
ods select modelinfo tests3 estimates; 
EQ5D VAS 
proc glimmix data=portrait.thesis; 
class siteid sex racewhite country; 
model eq5d_12  = AverageStressScore_w eq5d_b age sex racewhite country; 
random intercept/subject=siteid; 
estimate 'Average Stress Score per 1 pt increase' AverageStressScore_w 1/cl; 
ods select modelinfo tests3 estimates; 
run; 
 
MODEL 3 ADJUSTED FOR COMORBID CONDITIONS AND TREATMENT 
PAQ 
proc glimmix data=portrait.thesis; 
class siteid sex racewhite country currentsmoker hxhtn hxmi hxdm hxchf; 
model paqsumm_12  = AverageStressScore_w paqsumm_b age sex racewhite country 
currentsmoker hxhtn hxmi hxdm hxchf abivalue invtrt_3; 
random intercept/subject=siteid; 
estimate 'Average Stress Score per 1 pt increase' AverageStressScore_w 1/cl; 
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ods select modelinfo tests3 estimates; 
run; 
EQ5D VAS 
proc glimmix data=portrait.thesis; 
class siteid sex racewhite country; 
model eq5d_12  = AverageStressScore_w eq5d_b age sex racewhite country; 
random intercept/subject=siteid; 
estimate 'Average Stress Score per 1 pt increase' AverageStressScore_w 1/cl; 
ods select modelinfo tests3 estimates; 
run; 
 
MODEL 4 ADJUSTED FOR SOCIOECONOMIC STATUS 
PAQ 
proc glimmix data=portrait.thesis; 
class siteid sex racewhite country currentsmoker hxhtn hxmi hxdm hxchf notenoughfinance 
educhs_B avoidcarecost_b; 
model paqsumm_12  = AverageStressScore_w paqsumm_b age sex racewhite country 
currentsmoker hxhtn hxmi hxdm hxchf abivalue invtrt_3 notenoughfinance educhs_B 
avoidcarecost_b; 
random intercept/subject=siteid; 
estimate 'Average Stress Score per 1 pt increase' AverageStressScore_w 1/cl; 
ods select modelinfo tests3 estimates; 
EQ5D VAS 
proc glimmix data=portrait.thesis; 
class siteid sex racewhite country currentsmoker hxhtn hxmi hxdm hxchf notenoughfinance 
educhs_B avoidcarecost_b; 
model eq5d_12  = AverageStressScore_w eq5d_b age sex racewhite country currentsmoker 
hxhtn hxmi hxdm hxchf abivalue invtrt_3 notenoughfinance educhs_B avoidcarecost_b; 
random intercept/subject=siteid; 
estimate 'Average Stress Score per 1 pt increase' AverageStressScore_w 1/cl; 
ods select modelinfo tests3 estimates; 
run; 
 
MODEL 5 ADJUSTED FOR BASELINE DEPRESSION 
title2 'Adjusted for baseline depression score'; 
proc glimmix data=portrait.thesis; 
class siteid sex racewhite country currentsmoker hxhtn hxmi hxdm hxchf notenoughfinance 
educhs_B avoidcarecost_b; 
model paqsumm_12  = AverageStressScore_w paqsumm_b age sex racewhite country 
currentsmoker hxhtn hxmi hxdm hxchf abivalue invtrt_3 notenoughfinance educhs_B 
avoidcarecost_b phq8score_b; 
random intercept/subject=siteid; 
estimate 'Average Stress Score per 1 pt increase' AverageStressScore_w 1/cl; 
ods select modelinfo tests3 estimates; 
run; 
EQ5D  
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proc glimmix data=portrait.thesis; 
class siteid sex racewhite country currentsmoker hxhtn hxmi hxdm hxchf notenoughfinance 
educhs_B avoidcarecost_b; 
model eq5d_12  = AverageStressScore_w eq5d_b age sex racewhite country currentsmoker 
hxhtn hxmi hxdm hxchf abivalue invtrt_3 notenoughfinance educhs_B avoidcarecost_b 
phq8score_b; 
random intercept/subject=siteid; 
estimate 'Average Stress Score per 1 pt increase' AverageStressScore_w 1/cl; 
ods select modelinfo tests3 estimates; 
 
MORTALITY 
EXCLUSIONS 
Data mortality2; set mortality; 
if country = 1; 
if not missing (pssscore_b); 
AverageStressScore = mean(pssscore_b, pssscore_3, pssscore_6, pssscore_12); 
label averagestressscore = 'Average PSS Score over 12 months'; 
* 48 month mortality;   
if landmarkmo>48 then do;  
 landmarkmo48=48; fdeath48=0;  
end; 
 else do landmarkmo48=landmarkmo; fdeath48=fdeath_ndi; end;   
data numbermissing; set mortality2; 
nummiss = nmiss(of pssscore_b pssscore_3 pssscore_6 pssscore_12); 
run; 
proc freq data=numbermissing; 
tables nummiss; 
run; 
ods rtf file = "Missing mortality data &bettersysdate..rtf"; 
proc means data=mortality2 n nmiss; 
var age sex racewhite currentsmoker hxhtn hxmi hxdm hxchf abivalue invtrt_3 
notenoughfinance educhs_B avoidcarecost_b; 
run; 
data missing; set portrait.thesis; 
nummiss = nmiss(of age sex racewhite currentsmoker hxhtn hxmi hxdm hxchf abivalue 
notenoughfinance educhs_b avoidcarecost_b phq8score_b invtrt_3); 
run; 
proc freq data=missing; 
 
MORTALITY BY AGE GROUPS 
%cut(Data=mortality2, var=age, ngroups = 4, cutvar = agequart); 
proc phreg data=mortality2; 
class agequart avgpsspos/ref=first; 
model landmarkmo48*fdeath48(0) = agequart|avgpsspos; 
strata siteid; 
estimate 'Age 42-61: Stressed vs not' avgpsspos 1  /exp cl; 
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estimate 'Age 61-69: Stressed vs not' avgpsspos 1 agequart*avgpsspos 1 0 0 /exp cl; 
estimate 'Age 69-75: Stressed vs not' avgpsspos 1 agequart*avgpsspos 0 1 0/exp cl; 
estimate 'Age 75-94: Stressed vs not' avgpsspos 1 agequart*avgpsspos 0 0 1/exp cl; 
*ods select modelinfo nobs globaltests parameterestimates; 
 
COX MODELS 
model landmarkmo48*fdeath48(0) = averagestressscore|age/rl; 
strata siteid; 
ods select modelinfo nobs globaltests parameterestimates; 
run; 
UNADJUSTED 
ods rtf file = "Mortality models &bettersysdate..rtf"; 
title 'Unadjusted'; 
proc phreg data=mortality2; 
model landmarkmo48*fdeath48(0) = averagestressscore/rl; 
strata siteid; 
ods select modelinfo nobs globaltests parameterestimates; 
run; 
MODEL 1 ADUSTED FOR AGE 
title 'Adjusted for age'; 
proc phreg data=mortality2; 
model landmarkmo48*fdeath48(0) = averagestressscore age/rl; 
strata siteid; 
ods select modelinfo nobs globaltests parameterestimates; 
run; 
MODEL 2 ADJUSTED SEX AND RACE 
proc phreg data=mortality2; 
class sex racewhite/ref=first; 
model landmarkmo48*fdeath48(0) = averagestressscore age sex racewhite/rl; 
strata siteid; 
ods select modelinfo nobs globaltests parameterestimates; 
MODEL 3 ADJUSTED FOR COMORBIDITIES AND TREATMENT TYPE 
proc phreg data=mortality2; 
class sex racewhite currentsmoker hxhtn hxmi hxdm hxchf invtrt_3/ref=first; 
model landmarkmo48*fdeath48(0) = averagestressscore age sex racewhite currentsmoker hxhtn 
hxmi hxdm hxchf abivalue invtrt_3/rl; 
strata siteid; 
ods select modelinfo nobs globaltests parameterestimates; 
run; 
MODEL 4 ADJUSTED FOR SOCIOECONOMIC STATUS 
proc phreg data=mortality2; 
class sex racewhite currentsmoker hxhtn hxmi hxdm hxchf invtrt_3 notenoughfinance educhs_B 
avoidcarecost_b/ref=first; 
model landmarkmo48*fdeath48(0) = averagestressscore age sex racewhite currentsmoker hxhtn 
hxmi hxdm hxchf abivalue invtrt_3 notenoughfinance educhs_B avoidcarecost_b/rl; 
strata siteid; 
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ods select modelinfo nobs globaltests parameterestimates; 
MODEL 5 ADJUSTED FOR BASELINE DEPRESSION 
proc phreg data=mortality2; 
class sex racewhite currentsmoker hxhtn hxmi hxdm hxchf invtrt_3 notenoughfinance educhs_B 
avoidcarecost_b/ref=first; 
model landmarkmo48*fdeath48(0) = averagestressscore age sex racewhite currentsmoker hxhtn 
hxmi hxdm hxchf abivalue invtrt_3 notenoughfinance educhs_B avoidcarecost_b 
phq8score_b/rl; 
strata siteid; 
ods select modelinfo nobs globaltests parameterestimates; 
KAPLAN MEIER ANALYSIS 
UNADJUSTED KM CURVE 
title 'Unadjusted'; 
title2 'Stress binary'; 
proc lifetest data=mortality2 timelist = 0 to 48 by 6; 
time landmarkmo48*fdeath48(0); 
strata avgpsspos; 
AGE ADJUSTED 
proc phreg data=mortality2 plots(overlay)=survival; 
   class avgpsspos; 
   model landmarkmo48*fdeath48(0)=age avgpsspos; 
   baseline covariates=mortality2 outdiff=Diff1 survival=_all_/diradj group=avgpsspos; 
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